Literature DB >> 1988637

Quantification of hepatobiliary function as an integral part of imaging with technetium-99m-mebrofenin in health and disease.

E Doo1, G T Krishnamurthy, M J Eklem, S Gilbert, P H Brown.   

Abstract

A study was undertaken to check the feasibility of measuring the hepatic extraction fraction (HEF) and excretion T-1/2 values as an integral part of hepatobiliary imaging with technetium-99m-mebrofenin in health and disease. In 18 controls subjects, the HEF was 100% and the T-1/2 excretion mean +/- s.e. value was 15.23 +/- 1.4 min. The mean appearance times of the common bile duct (CBD), gallbladder (GB), and small intestine were 15.8 +/- 1.52, 20.2 +/- 2.7, and 23.8 +/- 3.08 min, respectively. Rising serum bilirubin in patients decreased HEF and increased T-1/2 excretion value resulting in delayed appearance of CBD, GB, and small intestine. In control subjects and patients with bilirubin less than 5 mg%, T-1/2 excretion values at 30, 40, and 50 min were similar to those values calculated using the entire 60 min of data, suggesting that the hepatic phase study time could be reduced to 30-40 min and still use the normal reference values established for 60 min. In patients with bilirubin greater than 5 mg%, the data collection duration should be continued for 60 min.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988637

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Spatially resolved assessment of hepatic function using 99mTc-IDA SPECT.

Authors:  Hesheng Wang; Yue Cao
Journal:  Med Phys       Date:  2013-09       Impact factor: 4.071

2.  Evaluation of (99m)technetium-mebrofenin and (99m)technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes.

Authors:  Brandon Swift; Wei Yue; Kim L R Brouwer
Journal:  Pharm Res       Date:  2010-07-22       Impact factor: 4.200

3.  Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI.

Authors:  Henrik Nilsson; Lennart Blomqvist; Lena Douglas; Anders Nordell; Eduard Jonas
Journal:  HPB (Oxford)       Date:  2010-10       Impact factor: 3.647

4.  Characterization of basal hepatic bile flow and the effects of intravenous cholecystokinin on the liver, sphincter, and gallbladder in patients with sphincter of Oddi spasm.

Authors:  Gerbail T Krishnamurthy; Shakuntala Krishnamurthy; Randy D Watson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-22       Impact factor: 9.236

5.  Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs.

Authors:  N D Pfeifer; S L Goss; B Swift; G Ghibellini; M Ivanovic; W D Heizer; L M Gangarosa; K L R Brouwer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-02

6.  Quantification of drug transport function across the multiple resistance-associated protein 2 (Mrp2) in rat livers.

Authors:  Pierre Bonnaventure; Catherine M Pastor
Journal:  Int J Mol Sci       Date:  2014-12-24       Impact factor: 5.923

7.  Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate.

Authors:  Izna Ali; Jason R Slizgi; Josh D Kaullen; Marija Ivanovic; Mikko Niemi; Paul W Stewart; Alfred S Barritt; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2017-12-22       Impact factor: 6.875

8.  Monitoring Hepatocyte Dysfunction and Biliary Complication After Liver Transplantation Using Quantitative Hepatobiliary Scintigraphy.

Authors:  Si-Juan Zou; Dong Chen; Yan-Zhao Li; Dun-Feng Du; Zhi-Shui Chen; Xiao-Hua Zhu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.